3-氧代环丁烷基羧酸 | 23761-23-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-氧代环丁烷基羧酸
• 中文别名: 3-氧代环丁羧酸；3-氧代环丁烷羧酸；3-氧-环丁烷羧酸；三氧代环丁烷基羧酸；3-氧代环丁烷甲酸；4- [5- [4-(戊氧基)苯基] -3-异恶唑基]苯甲酸
• 英文名称: 3-oxocyclobutanecarboxylic acid
• 英文别名: 3-oxocyclobutane-1-carboxylic acid；3-oxocyclobutylcarboxylic acid；cyclobutanone-3-carboxylic acid
• CAS: 23761-23-1
• 化学式: C₅H₆O₃
• mdl: MFCD00100900
• 分子量: 114.101
• InChiKey: IENOFRJPUPTEMI-UHFFFAOYSA-N

物化性质

• 熔点：
  69-70℃
• 沸点：
  296°C
• 密度：
  1.431
• 闪点：
  147°C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• TSCA：
  No
• 海关编码：
  2918300090
• 储存条件：
  | 室温 |

SDS

3-Oxocyclobutanecarboxylic Acid Revision number: 6
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: 3-Oxocyclobutanecarboxylic Acid

Revision number: 6

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Skin corrosion/irritation Category 2
Category 2A
Serious eye damage/eye irritation
ENVIRONMENTAL HAZARDS Not classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal word Warning
Hazard statements Causes skin irritation
Causes serious eye irritation
Precautionary statements:
Wash hands thoroughly after handling.
[Prevention]
Wear protective gloves/eye protection/face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
[Response]
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: 3-Oxocyclobutanecarboxylic Acid
Percent: >97.0%(GC)(T)
CAS Number: 23761-23-1
Chemical Formula: C5H6O3

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
3-Oxocyclobutanecarboxylic Acid

---

Section 4. FIRST AID MEASURES
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Comply with laws.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Safety glasses. A face-shield, if the situation requires.
Eye protection:
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Crystal- Powder
Form:
Colour: White - Very pale yellow
No data available
Odour:
pH: No data available
Melting point/freezing point:70°C
3-Oxocyclobutanecarboxylic Acid

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Boiling point/range: No data available
Flash point: No data available
Flammability or explosive
limits:
Lower: No data available
Upper: No data available
Relative density: No data available
Solubility(ies):
[Water] No data available
No data available
[Other solvents]

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents, Bases
Hazardous decomposition Carbon monoxide, Carbon dioxide
products:

---

Section 11. TOXICOLOGICAL INFORMATION
No data available
Acute Toxicity:
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
No data available
IARC =
NTP = No data available
No data available
Reproductive toxicity:

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobility in soil
Log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not listed
3-Oxocyclobutanecarboxylic Acid

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备

一种医药中间体3-氧代环丁烷基羧酸的合成方法，其特征在于以羧酸为原料，在溶剂甲醇的作用下，于120℃至150℃温度范围内先与3,3-二甲氧基环丁烷-1,1-二羧酸二异丙酯反应，随后通过烷基化生成3-氧代环丁烷基羧酸。

用途

3-氧代环丁烷基羧酸是一种无色液体，广泛应用于科学研究、医药中间体及有机合成中间体等领域。

应用

3-氧代环丁烷基羧酸是一个重要的医药中间体，被用于多种原料药的合成。具体包括ACKl抗体、MDM2拮抗剂、JAK抑制剂、CETP抑制剂、激酶抑制剂、PDE10抑制剂以及凝血酶抑制剂等。此外，在自身免疫慢性炎症和抗肿瘤药物中也均有应用。

合成方法

将3,3-二甲氧基环丁烷-1,1-二羧酸二异丙酯（2.2 g，7.63 mmol）溶解于HCl（6 N，6 mL），在155-160℃下加热。随后用乙醚（150 mL）稀释反应混合物，并在室温下剧烈搅拌。醚层经MgSO4干燥、过滤并浓缩后，得到棕色固体的3-氧代环丁烷基羧酸（1.0 g），产率高达118%。

核磁共振谱图显示：1H NMR（500 MHz，CDCl3）δ ppm 10.80 (1H, br.s)，3.43-3.51 (2H, m)，3.26-3.40 (3H, m)；13C NMR（126 MHz，CDCl3）δ ppm 203.14、180.17、51.64（2℃，s）、27.32（1℃，s）。


反应信息

• 作为反应物：
  描述：

  3-氧代环丁烷基羧酸 在 lithium aluminium tetrahydride 、 二乙胺基三氟化硫 作用下， 以 乙醚 、 二氯甲烷 、 甲苯 为溶剂， 反应 8.26h， 生成 (3,3-二氟环丁基)甲醇
  参考文献：
  名称：

  C4 / C5 3,3-二氟环丁基取代的结构单元的多重图合成

  摘要：

  摘要 描述了一种3,3-二氟环丁基取代的结构单元（包括羧酸，胺，醇，叠氮化物，三氟硼酸酯）的多谱图合成方法。结果表明，在大多数情况下，3,3-二氟环丁烷甲酸乙酯是获得目标衍生物的方便的常用合成中间体。为了制备3，3-二氟环丁醇或-环丁酮，应采用通过二氯乙烯酮与叔丁基或苄基乙烯基醚反应的替代途径。 描述了一种3,3-二氟环丁基取代的结构单元（包括羧酸，胺，醇，叠氮化物，三氟硼酸酯）的多谱图合成方法。结果表明，在大多数情况下，3,3-二氟环丁烷甲酸乙酯是获得目标衍生物的方便的常用合成中间体。为了制备3，3-二氟环丁醇或-环丁酮，应采用通过二氯乙烯酮与叔丁基或苄基乙烯基醚反应的替代途径。

  DOI：

  10.1055/s-0037-1610237
• 作为产物：
  描述：

  3-亚甲基环丁基甲腈 在 potassium osmate(VI) dihydrate 、 sodium periodate 、 水 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 3-氧代环丁烷基羧酸
  参考文献：
  名称：

  [EN] CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR
  [FR] INHIBITEUR DE CETP SUBSTITUÉ PAR DES AMINES CYCLIQUES À BASE D'OXAZOLIDINONE

  摘要：

  具有公式I结构的化合物，包括这些化合物的药用盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。在公式I的化合物中，A3是一个取代苯基或茚基。公式（I）。

  公开号：

  WO2012058187A1
• 作为试剂：
  描述：

  3-氧代环丁烷基羧酸 、 1-(4-溴-2-氟苯甲基)吡咯烷 在 3-氧代环丁烷基羧酸 作用下， 以63的产率得到cis-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-3-hydroxy-N-(2-methylpropyl)cyclobutanecarboxamide
  参考文献：
  名称：

  J. Med. Chem. 2011, 54, 7602-7620

  摘要：

  DOI：

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015180612A1

  公开（公告）日：2015-12-03

  Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

  揭示了新型视黄醇相关孤儿受体γ（RORγ）调节剂及其在通过RORγ介导的疾病治疗中的应用。
• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012169649A1

  公开（公告）日：2012-12-13

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

  本发明涉及一种新型吲唑基或吡咯吡啶基衍生物，由下面的式（1）表示，该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用，并且包括含有该衍生物的药物组合物。式（1）[其中每个取代基如权利要求1所定义]
• Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors
  作者：Fabian Heider、Francesco Ansideri、Roberta Tesch、Tatu Pantsar、Urs Haun、Eva Döring、Mark Kudolo、Antti Poso、Wolfgang Albrecht、Stefan A. Laufer、Pierre Koch

  DOI：10.1016/j.ejmech.2019.04.035

  日期：2019.8

  Alzheimer's disease. A set of 39 compounds was synthesized and evaluated in kinase activity assays for their ability to inhibit both target kinases. Among the synthesized compounds, potent dual-target-directed inhibitors showing IC50 values down to the low double-digit nanomolar range, were identified. One of the best balanced dual inhibitors presented in here is N-(4-(2-ethyl-4-(4-fluorophenyl)-1H-imidazol

  同时抑制参与同一复杂疾病进展的两个靶标的化合物可能会表现出累加甚至协同的治疗作用。在这里，我们介绍了2,4,5-三取代的咪唑类化合物，作为p38α丝裂原活化蛋白激酶和糖原合酶激酶3β（GSK3β）的双重抑制剂。两种酶都是神经退行性疾病（例如阿尔茨海默氏病）的潜在治疗靶标。合成了39种化合物，并在激酶活性测定中评估了它们抑制两种靶激酶的能力。在合成的化合物中，鉴定出了显示出低至两位数纳摩尔范围低的IC 50值的有效的双靶标抑制剂。这里介绍的最佳平衡双重抑制剂之一是N-（4-（2-乙基-4-（4-氟苯基）-1 H-咪唑-5-基）吡啶-2-基）环丙烷甲酰胺（20c）（p38α，IC 50  = 16 nM;GSK3β，IC 50 = 35 nM）具有优异的代谢稳定性和比密切相关的GSK3α明显的同工型选择性。我们的发现通过基于先前发布的X射线结构的计算机对接研究得到了合理化。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。